XENE - Xenon Pharmaceuticals Inc.
IEX Last Trade
40.12
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:01:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$40.12
-1.75
0.05%
Fundamental analysis
15%
Profitability
8%
Dept financing
2%
Liquidity
75%
Performance
10%
Performance
5 Days
-6.42%
1 Month
-6.12%
3 Months
-2.57%
6 Months
3.26%
1 Year
-13.44%
2 Year
-1.20%
Key data
Stock price
$40.12
DAY RANGE
$38.38 - $40.12
52 WEEK RANGE
$36.84 - $50.99
52 WEEK CHANGE
-$13.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Ian C. Mortimer
Region: US
Website: xenon-pharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xenon-pharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.
Recent news